Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023		Jun. 30, 2022
Revenue	$ 5,069	$ 5,809	$ 13,764		$ 10,461
Cost of revenue	3,681	4,368	9,943		8,254
Gross profit	1,388	1,441	3,821		2,207
Operating expenses:
Research and development	559	569	1,161		879
Selling and shipping	428	332	847		605
General and administrative	1,360	1,287	2,960		2,443
Loss on disposition of Tantaline	162	0	162		0
Impairment charge	111	0	111		0
Total operating expenses	2,620	2,188	5,241		3,927
Operating loss	(1,232)	(747)	(1,420)	[1]	(1,720)
Other income (expense):
Interest income	107	13	227		31
Interest expense	(6)	0	(12)		(5)
Foreign exchange income (expense)	15	(110)	43		(147)
Other income	13	6	20		5
Total other income, net	129	(91)	278		(116)
Loss before income taxes	(1,103)	(838)	(1,142)	[1]	(1,836)
Income tax expense	10	1	11		1
Net loss	$ (1,113)	$ (839)	$ (1,153)		$ (1,837)
Loss per common share - basic (in dollars per share)	$ (0.16)	$ (0.12)	$ (0.17)		$ (0.27)
Loss per common share - diluted (in dollars per share)	$ (0.16)	$ (0.12)	$ (0.17)		$ (0.27)
Weighted average common shares outstanding:
Basic (in shares)	6,778,754	6,728,938	6,776,035		6,726,990
Diluted (in shares)	6,778,754	6,728,938	6,776,035		6,726,990

[1] Includes loss on sale of Tantaline of $0.2 million and impairment charge related to MesoScribe fixed assets of $0.1 million.